--- title: "Microbot Medical (MBOT) news: offering" url: "https://aibio.space/companies/microbot-medical/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "MBOT offering news: Microbot Medical agrees to $13.0 million registered direct offering at $2.13 per share. Microbot Medical Inc." --- MBOT Microbot Medical Inc. NASDAQ · United States # Microbot Medical (MBOT) news MBOT offering news Financings · 2025-10-03 ## [Microbot Medical holder exercises 600,000 options at $2.10 and gets Series J options](https://aibio.space/news/microbot-medical-holder-exercises-600-000-options-2-10-gets-series/) Under a September 14, 2025 inducement agreement, a holder exercised 600,000 series H options and received 600,000 series J options. A separate exercise of 374,167 options produced gross proceeds of approximately $896,000. ## Latest Microbot Medical news 1. 2025-09-16 Financings [Microbot Medical expects $25.2 million from first closing of option exercises](https://aibio.space/news/microbot-medical-expects-25-2-million-first-closing-option-exercises/) A second closing should add about $4 million. New series J options could bring about $63 million more if fully exercised. 2. 2025-02-11 Financings [Microbot Medical agrees to $13.0 million registered direct offering at $2.13 per share](https://aibio.space/news/microbot-medical-agrees-13-0-million-registered-direct-offering-2-13/) Microbot Medical agreed to sell 6,103,289 shares at $2.13 in a registered direct offering, with unregistered warrants for up to 12,206,578 more shares. H.C. Wainwright & Co., LLC is the exclusive placement agent, and the company pays it a 7.0% cash fee. ## Microbot Medical at a glance - **Ticker**: MBOT - **Listing**: NASDAQ - **Country**: United States - **Cash, Jun 30, 2026**: $67.4 million ### Related companies - [Solid Biosciences](https://aibio.space/companies/solid-biosciences/) NASDAQ: SLDB - [Halozyme Therapeutics](https://aibio.space/companies/halozyme-therapeutics/) NASDAQ: HALO - [AFFYMAX INC](https://aibio.space/companies/affymax/) OTC: AFFY - [Immunovant](https://aibio.space/companies/immunovant/) NASDAQ: IMVT - [Calithera Biosciences](https://aibio.space/companies/calithera-biosciences/) OTC: CALA - [Jasper Therapeutics](https://aibio.space/companies/jasper-therapeutics/) NASDAQ: JSPR - [Enliven Therapeutics](https://aibio.space/companies/enliven-therapeutics/) NASDAQ: ELVN - [Summit Therapeutics](https://aibio.space/companies/summit-therapeutics/) NASDAQ: SMMT ### Also on NASDAQ - [BioVie](https://aibio.space/companies/biovie/) BIVI - [Nano-X Imaging](https://aibio.space/companies/nano-x-imaging/) NNOX - [Capricor Therapeutics](https://aibio.space/companies/capricor-therapeutics/) CAPR - [Amneal Pharmaceuticals](https://aibio.space/companies/amneal-pharmaceuticals/) AMRX - [TACTILE SYSTEMS TECHNOLOGY INC](https://aibio.space/companies/tactile-systems-technology/) TCMD - [MiMedx Group](https://aibio.space/companies/mimedx/) MDXG ## What Microbot Medical does Microbot Medical is a commercial-stage company whose sole product is the LIBERTY Endovascular Robotic Surgical System. The company operates through its wholly owned Israeli subsidiary, Microbot Medical Ltd. Its business depends heavily on the commercial success of LIBERTY, and it says its future revenue from LIBERTY and any other products it develops will be affected by the size of the commercial opportunity. Microbot has not recognized any revenues through December 31, 2025, and expects to need additional funding to become a profitable commercial enterprise. Its products depend on third-party reimbursement for procedures and on regulatory clearances in other countries. The company relies on third-party manufacturers and component suppliers, and on contract research organizations, collaborative academic groups and clinical trial sites for any future clinical trials. Its risk summary also notes that its Israeli facilities expose it to political and military conditions in Israel. | Product or program | What it is | Stage | |---|---|---| | LIBERTY Endovascular Robotic Surgical System | Robotic surgical system for endovascular procedures; the company's sole product | Commercial-stage company; described as its sole product | Summarised from the company's [10-K filed Mar 26, 2026](https://www.sec.gov/Archives/edgar/data/883975/000149315226012935/form10-k.htm). ## Microbot Medical annual financials | Line | FY2025 | FY2024 | |---|---|---| | Research and development | [$6.3 million](https://www.sec.gov/Archives/edgar/data/883975/000149315226012935/) | [$6.6 million](https://www.sec.gov/Archives/edgar/data/883975/000149315226012935/) | | Net income (loss) | [-$13.1 million](https://www.sec.gov/Archives/edgar/data/883975/000149315226012935/) | [-$11.4 million](https://www.sec.gov/Archives/edgar/data/883975/000149315226012935/) | | Cash from operations | [-$13.0 million](https://www.sec.gov/Archives/edgar/data/883975/000149315226012935/) | [-$8.8 million](https://www.sec.gov/Archives/edgar/data/883975/000149315226012935/) | | Cash and equivalents | [$3.9 million](https://www.sec.gov/Archives/edgar/data/883975/000149315226037009/) | [$3.1 million](https://www.sec.gov/Archives/edgar/data/883975/000149315226012935/) | | Short-term investments | [$74.7 million](https://www.sec.gov/Archives/edgar/data/883975/000149315226037009/) | [$2.4 million](https://www.sec.gov/Archives/edgar/data/883975/000149315226012935/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $3.2 million, plus short-term investments of $64.2 million, $67.4 million in all. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Microbot Medical Has Microbot Medical raised money recently? Our latest story on this, dated Feb 11, 2025: "Microbot Medical agrees to $13.0 million registered direct offering at $2.13 per share". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/microbot-medical-agrees-13-0-million-registered-direct-offering-2-13/). What is the ticker symbol of Microbot Medical? Microbot Medical Inc. trades under the ticker MBOT on NASDAQ. Where is Microbot Medical listed? Microbot Medical Inc. is listed on NASDAQ. Our directory also records these other listings: GETTEX:CY9D. What is the SEC CIK of Microbot Medical? The SEC Central Index Key (CIK) for Microbot Medical Inc. is 883975. Its filings are on SEC EDGAR. How many shares does Microbot Medical have outstanding? 67,164,801 shares as of 2026-08-11, per the cover page of its 10-Q filed 2026-08-11. Which country or territory is Microbot Medical listed under? Our directory records Microbot Medical Inc. under United States. What does Microbot Medical do? Our directory classifies Microbot Medical Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline. What is the ISIN of Microbot Medical? The ISIN recorded for Microbot Medical Inc. is US59503A2042. Does aibio.space cover Microbot Medical? aibio.space lists Microbot Medical Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is Microbot Medical incorporated? SEC records list its state or country of incorporation as DE. What does Microbot Medical develop? Microbot Medical is a commercial-stage company whose sole product is the LIBERTY Endovascular Robotic Surgical System. The company operates through its wholly owned Israeli subsidiary, Microbot Medical Ltd. Its business depends heavily on the commercial success of LIBERTY, and it says its future revenue from LIBERTY and any other products it develops will be affected by the size of the commercial opportunity. What is LIBERTY Endovascular Robotic Surgical System from Microbot Medical? LIBERTY Endovascular Robotic Surgical System: Robotic surgical system for endovascular procedures; the company's sole product Stage: Commercial-stage company; described as its sole product. Is Microbot Medical profitable? Microbot Medical Inc. reported a net loss of $13.1 million for the fiscal year ended Dec 31, 2025, and used $13.0 million of cash in operations, per its annual report to the SEC. How much does Microbot Medical spend on research and development? $6.3 million in the fiscal year ended Dec 31, 2025, per its annual report. How much cash does Microbot Medical have? $67.4 million in cash and short-term investments at Jun 30, 2026, per its 10-Q. ## Investor discussion: Microbot Medical Members talk about Microbot Medical (MBOT). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Microbot Medical, newest first. Each line links the filing it comes from. 1. 2026-04-10 Financings Reported a financing. SEC Form 8-K (Items 8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/883975/000149315226016198/form8-k.htm) 2. 2025-09-19 Distress Reported a leadership departure tied to a disagreement or a restructuring. SEC Form 8-K (Items 5.02). [Source](https://www.sec.gov/Archives/edgar/data/883975/000149315225014263/form8-k.htm) 3. 2025-09-16 Financings Reported a financing. SEC Form 8-K (Items 1.01,3.02,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/883975/000149315225013743/ex99-1.htm) 4. 2025-08-25 Financings Reported an unregistered sale of its securities. SEC Form 8-K (Items 3.02,9.01). [Source](https://www.sec.gov/Archives/edgar/data/883975/000164117225025390/form8-k.htm) 5. 2025-06-11 Listings Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 3.03,5.03,5.07,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/883975/000164117225014622/form8-k.htm) 6. 2025-03-10 Financings Set up an at-the-market program to sell shares over time. SEC Form S-3. [Source](https://www.sec.gov/Archives/edgar/data/883975/000149315225009734/forms-3.htm) 7. 2025-02-04 Financings Reported a financing. SEC Form S-1. [Source](https://www.sec.gov/Archives/edgar/data/883975/000149315225004863/forms-1.htm) 8. 2025-01-27 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/883975/000149315225003818/form8-k.htm) 9. 2024-12-19 Listings Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.02,5.07,9.01). [Source](https://www.sec.gov/Archives/edgar/data/883975/000149315224050799/form8-k.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:MBOT on TradingView](https://www.tradingview.com/symbols/NASDAQ-MBOT/). ## SEC filings and registration - **SEC name**: Microbot Medical Inc. - **CIK**: 883975 - **Industry (SIC)**: Surgical & Medical Instruments & Apparatus (3841) - **US tickers**: MBOT (Nasdaq) - **State or country of incorporation**: DE - **Fiscal year ends**: December 31 - **Filer category**: Non-accelerated filer
Smaller reporting company - **Business address**: 25 RECREATION PARK DR SUITE 108, HINGHAM, MA, 02043 - **Phone**: 908-938-5561 - **Shares outstanding**: 67,164,801 as of 2026-08-11 (10-Q filed 2026-08-11) - **Former names**: Microbot Medical Inc.; STEMCELLS INC; CYTOTHERAPEUTICS INC/DE ### Recent filings (8-K and 6-K are the company's own announcements) - [8-K](https://www.sec.gov/Archives/edgar/data/883975/000149315226047702/form8-k.htm) filed 2026-10-20 - [8-K](https://www.sec.gov/Archives/edgar/data/883975/000149315226045866/form8-k.htm) filed 2026-10-06 - [8-K](https://www.sec.gov/Archives/edgar/data/883975/000149315226044429/form8-k.htm) filed 2026-09-28 - [8-K](https://www.sec.gov/Archives/edgar/data/883975/000149315226037031/form8-k.htm) filed 2026-08-11 - [10-Q](https://www.sec.gov/Archives/edgar/data/883975/000149315226037009/form10-q.htm) filed 2026-08-11 - [8-K](https://www.sec.gov/Archives/edgar/data/883975/000149315226036600/form8-k.htm) filed 2026-08-07 - [8-K](https://www.sec.gov/Archives/edgar/data/883975/000149315226034014/form8-k.htm) filed 2026-07-21 - [8-K](https://www.sec.gov/Archives/edgar/data/883975/000149315226032260/form8-k.htm) filed 2026-07-07 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000883975), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Microbot Medical Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker MBOT, recorded under United States. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Microbot Medical Inc. - **Ticker**: MBOT - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Biotechnology - **ISIN**: US59503A2042 - **Other listed symbols**: GETTEX:CY9D - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-MBOT/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/microbot-medical/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Microbot Medical (MBOT) news: offering", 2026-10-31, https://aibio.space/companies/microbot-medical/